ACR/ARHP 2018 Annual Meeting
A reduction in risk for cardiovascular disease has been reported among patients with rheumatoid arthritis who are receiving concomitant therapy with methotrexate and biologic disease-modifying antirheumatic drugs.
ACR/ARHP 2018 Annual Meeting
Although the incidence rate of venous thromboembolism was numerically higher in patients treated with tofacitinib vs TNF inhibitors, the risk was not statistically significant.
ACR/ARHP 2018 Annual Meeting
The researchers concluded their findings indicate that for patients with RA, abatacept reduced the risk for diabetes and "potentially improved insulin sensitivity and glycemic profile."
ACR/ARHP 2018 Annual Meeting
The results support combination therapy with intra-articular steroid injections and tofacitinib to achieve clinical and radiographic remission in patients with early rapid radiographic progression RA.
ACR/ARHP 2018 Annual Meeting
Tofacitinib extended release has comparable clinical efficacy to tofacitinib administered twice daily.
ACR/ARHP 2018 Annual Meeting
Among a new line of biological and targeted synthetic DMARD, ustekinumab and secukinumab have shown favorable safety and efficacy profiles for psoriasis and arthritis, respectively in patients with psoriatic arthritis.
ACR/ARHP 2018 Annual Meeting
Patients treated with JAK inhibitors for rheumatoid arthritis may be less likely to have low disease activity if they are obese compared with those who are overweight.
ACR/ARHP 2018 Annual Meeting
A diagnosis of cardiovascular disease or presence of related biomarkers, as well as the use of antirheumatic drugs may be associated with a higher risk for heart failure in patients with rheumatoid arthritis.
